Expanded coverage under a Medicare-Medicaid partnership to treat all prevalent cases of hepatitis C appears to be cost-effective by saving money and improving patient outcomes.

Discovery of Hepatitis C Virus Brings Nobel Prize

By Mary Caffrey

October 5th 2020

Two Americans and a British scientist share the 2020 Prize for Physiology or Medicine for work in the 1970s through the 1990s. The rise of agents to treat hepatitis C virus has created vexing questions in managed care.

HIV, Hepatitis C Testing Rates Remain Dismal Among Injection Drug Users

By Maggie L. Shaw

April 17th 2020

Despite being at an increased risk for HIV and hepatitis C, persons who inject drugs (PWID) are tested at dismal rates for both: just 8.6% and 7.7%, respectively, according to data from 2010 to 2017. PWID who live in rural communities are more likely to face barriers to adequate testing and care for both diseases.

Updated Hepatitis C Screening Recommendations Expand to Cover Adolescents, DAAs

By Maggie L. Shaw

March 2nd 2020

Hepatitis C virus (HCV) has contributed to more US patient deaths than the next 60 reportable infectious diseases combined. The United States Preventive Services Task Force has issued updated guidelines on screening for HCV that account for the larger proportion of this patient group that now includes persons who inject drugs, as well as the shift from interferon-based therapy to regimens composed of direct-acting antiviral (DAA) medications.

From the Editorial Board: Jeffrey D. Dunn, PharmD, MBA

By Jeffrey D. Dunn, PharmD, MBA

February 15th 2020

...

3 4 5 6 7

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions